Tide Pharmaceutical (03880)

Teide Pharmaceutical (Zhejiang) Co., Ltd. (stock code 03880.HK) is a contract research, development and production organization (CRDMO) specializing in polypeptides, providing full-cycle services from early discovery, pre-clinical, clinical development to commercial production. Headquartered in Hangzhou, China, it has commercial production bases and offices in China and the United States, and has been deeply engaged in the field of polypeptides for more than 20 years. Provides CRO (polypeptide new chemical molecular entity discovery synthesis) and CDMO (polypeptide CMC development and commercial production) services, and has extended to oligonucleotide CDMO since 2021. It has provided more than 1,000 customers worldwide with support for the synthesis, development, production and CMC declaration of polypeptides that meet the regulatory requirements of major markets around the world. The project covers more than 50 countries such as China, the United States, Japan, Europe, South Korea and Australia. Clients include large pharmaceutical companies, biotech companies, virtual pharmaceuticals and start-ups. The peptide biochemical tirpopeptide drug substance in the subsidiary has completed the US FDA DMF registration.

Tide Pharmaceutical (03880) is located at No. 12, Bangongdizhizhejiangshenghangzhoushiqiantangqu Avenue Hao, China.

Main peptides produced: Cagrilintide, Tirzepatide, Retatrutide, Semaglutide, Liraglutide, Thymopentin (TP-5).

Website: https://www.medtideinc.com